Keyphrases
Protein Kinase C Inhibitor
100%
Sotrastaurin
100%
Transplant Rejection
100%
Psoriasis Treatment
100%
Allograft Rejection
50%
Inflammatory Diseases
50%
T Cell Activation
33%
Immunosuppressive Drugs
33%
Adverse Effects
16%
Clinical Trials
16%
Inflammatory Response
16%
Rodents
16%
Graft Rejection
16%
Safety Profile
16%
Nonhuman Primate
16%
Phase I Trial
16%
Renal Transplantation
16%
Transplantation Tolerance
16%
Specific Inhibitor
16%
Autoimmune
16%
In Vivo Data
16%
Clinical Assessment
16%
Liver Transplantation
16%
Phase II Trial
16%
Data Needs
16%
Severe Adverse Effects
16%
Kidney Transplant Recipients
16%
Psoriasis
16%
Immune Cell Function
16%
Efficacy Profile
16%
Novartis
16%
Histological Assessment
16%
Long-term Graft Survival
16%
Clinical Trial Data
16%
Medicine and Dentistry
Graft Rejection
100%
Protein Kinase C Inhibitor
100%
Psoriasis
100%
Sotrastaurin
100%
Inflammatory Disorder
50%
Adverse Event
33%
Clinical Trial
33%
Immunosuppressive Drug
33%
T Cell Activation
33%
Immunocompetent Cell
16%
Serositis
16%
Transplantation
16%
Cell Function
16%
Kidney Transplantation
16%
Graft Survival
16%
Kidney Graft
16%
Immunosuppressant
16%
Liver Transplantation
16%
Phase I Trials
16%
Phase II Trials
16%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Kinase C Inhibitor
100%
Graft Rejection
100%
Psoriasis
100%
Sotrastaurin
100%
Immunosuppressive Agent
50%
Inflammatory Disease
50%
Clinical Trial
33%
Adverse Event
33%
Inflammation
16%
Phase II Trials
16%
Phase I Trials
16%
Immunology and Microbiology
Transplant Rejection
100%
Sotrastaurin
100%
Inflammatory Disorder
50%
T Cell Activation
33%
Transplant Procedure
33%
Immunosuppressive Drug
33%
Immunocompetent Cell
16%
Inflammation Response
16%
Kidney Transplantation
16%
Cell Function
16%
Liver Transplantation
16%